

Literature list 2023 including Impact Factor

NB online ahead of print, final publication date has yet to be determined.

This list is arranged alphabetically by first author.

1. van Andel E, **Bijlenga D**, Vogel SWN, Beekman ATF, Kooij JJS. Cardiovascular risk in adults with Delayed Sleep Phase Syndrome (DSPS) and Attention-Deficit/Hyperactivity Disorder (ADHD). *Chronobiol Int*. 2023 Dec 2;40(12):1566-1573. doi: 10.1080/07420528.2023.2287058. Epub 2023 Dec 5. PMID: 38017699 (Impact Factor 2.8)
2. **Aronica E**, Ciusani E, Coppola A, Costa C, Russo E, Salmaggi A, Perversi F, Maschio M. Epilepsy and brain tumors: Two sides of the same coin. *J Neurol Sci*. 2023 Mar 15;446:120584. doi: 10.1016/j.jns.2023.120584 (Impact Factor 4.4)
3. **Aronica E**, Specchio N, Luinenburg MJ, Curatolo P. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy. *Brain*. 2023 Jul 3;146(7):2694-2710. doi: 10.1093/brain/awad048 (Impact Factor 14.5)
4. Barone V, Piastra MC, van Dijk JP, **Visser GH**, Debeij-van Hall MHJA, van Putten MJAM. Neurophysiological signatures reflect differences in visual attention during absence seizures. *Clin Neurophysiol*. 2023 May 26;152:34-42. doi: 10.1016/j.clinph.2023.05.007. PMID: 37269771 (Impact Factor 4.7)
5. Benoist C, Boccaletti S, Leach JP, Cattaneo A, Chaplin A, Antunes L, Heiman F, **Sander JW**. Characterising people with focal drug-resistant epilepsy: A retrospective cohort study. *Epilepsy Behav*. 2023 Dec;149:109540. doi: 10.1016/j.yebeh.2023.109540. (Impact Factor 2.6)
6. Besten-Bertholee DD, **Wegner I**, Touw DJ, Ter Horst PGJ. Analytical and clinical validation of an LC-MS/MS method for carbamazepine, lamotrigine and levetiracetam in dried blood spots. *Eur J Hosp Pharm*. 2023 Mar 9;ejhpharm-2022-003589. doi: 10.1136/ejhpharm-2022-003589. Online ahead of print. PMID: 36894298 (Impact Factor 1.7)
7. **Bijlenga D**, **Fronczek R**, **Gorter EJ**, **Thijs RD**. Vigilance and circadian function in daytime and nocturnal epilepsy compared to controls. *Epilepsy Res*. 2023 Nov;197:107238. doi: 10.1016/j.eplesyres.2023.107238. (Impact Factor 2.2)
8. **van Blooijis D**, van den Boom MA, van der Aar JF, Huiskamp GM, Castegnaro G, Demuru M, Zweiphenning WJEM, van Eijsden P, Miller KJ, Leijten FSS, Hermes D. Developmental trajectory of transmission speed in the human brain. *Nat Neurosci*. 2023 Apr;26(4):537-541 doi: 10.1038/s41593-023-01272-0. (Impact Factor 25)
9. Boele FW, den Otter PWM, **Reijneveld JC**, de Witt Hamer PC, **van Thuijl HF**, Lorenz LMC, Wesseling P, Lagerwaard FJ, Taphoorn MJB, Kouwenhoven MCM, Snijders TJ, Douw L, Klein M. Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: A longitudinal study spanning two decades. *Neuro Oncol*. 2023 Feb 14;25(2):351-364. doi: 10.1093/neuonc/noac185. PMID: 35908832 (Impact Factor 15.9)
10. Boothman I, Clayton LM, McCormack M, Driscoll AM, Stevelink R, Moloney P, Krause R, Kunz WS, Diehl S, O'Brien TJ, Sills GJ, **de Haan GJ**, Zara F, Koeleman BP, Depondt C, Marson AG, Stefansson H, Stefansson K, Craig J, Johnson MR, Striano P, Lerche H, Furney SJ, Delanty N; Consortium EpiPGX; Sisodiya SM, Cavalleri GL. Testing for pharmacogenomic predictors of ppRNFL thinning in individuals exposed to vigabatrin. *Front Neurosci*. 2023 Sep 8;17:1156362. doi: 10.3389/fnins.2023.1156362. PMID: 37790589 (Impact Factor 4.3)
11. Brandt RB, Mulleners W, Wilbrink LA, Brandt P, van Zwet EW, Huygen FJ, Ferrari MD, **Fronczek R**; ICON study group. Intra- and interindividual attack

- frequency variability of chronic cluster headache. *Cephalalgia*. 2023 Feb;43(2):3331024221139239. doi: 10.1177/03331024221139239. PMID: 36739508 (Impact Factor 4.9)
12. Brandt RB, Naber WC, Ouwehand RH, Haan J, Ferrari MD, **Fronczek R**. Transient side shift of cluster headache attacks after unilateral greater occipital nerve injection. *Headache*. 2023 Sep;63(8):1193–1197. doi: 10.1111/head.14587. Epub 2023 Jun 26. PMID: 37358558 (Impact Factor 5)
 13. Brandt RB, Wilbrink LA, de Coo IF, Haan J, Mulleners WM, Huygen FJPM, van Zwet EW, Ferrari MD, **Fronczek R**; ICON study group. A prospective open label 2–8 year extension of the randomised controlled ICON trial on the long-term efficacy and safety of occipital nerve stimulation in medically intractable chronic cluster headache. *EBioMedicine*. 2023 Dec;98:104895. doi: 10.1016/j.ebiom.2023.104895. Epub 2023 Nov 25. PMID: 38007947; PMCID: PMC10755111 (Impact Factor 11.1)
 14. Brigo F, Zelano J, Abaira L, Bentes C, Ekdahl CT, Lattanzi S, Ingvar Lossius M, Redfors P, Rouhl RPW, Russo E, **Sander JW**, Vogrig A, Wickström R. Proceedings of the "International Congress on Structural Epilepsy & Symptomatic Seizures" (STESS, Gothenburg, Sweden, 29–31 March 2023). *Epilepsy Behav*. 2024 Jan;150:109538 doi: 10.1016/j.yebeh. 2023.109538. (Impact Factor 2.6)
 15. Buimer HP, Siebelink NM, Gaasterland A, van Dam K, **Smits A**, Frederiks K, van der Poel A. Sleep-wake monitoring of people with intellectual disability: Examining the agreement of EMFIT QS and actigraphy. *J Appl Res Intellect Disabil*. 2023 Nov;36(6):1276–1287. doi: 10.1111/jar.13146. PMID: 37489295 (Impact Factor unknown)
 16. Caramanna I, **Reijneveld JC**, van de Ven PM, van den Bent M, Idbaih A, Wick W, Taphoorn MJB, Dirven L, Bottomley A, Klein M; EORTC Quality of Life Group and EORTC Brain Tumor Group. Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials. *Eur J Cancer*. 2023 Jun;186:38–51. doi: 10.1016/j.ejca.2023.02.029. (Impact Factor 8.4)
 17. Coelho P, Madureira J, Franco A, Peralta AR, Bentes C, Campos AR, Anink J, **Aronica E**, Roque R, Pimentel J. Histopathological characterization of cerebral small vessel disease in epilepsy patients with temporal lobe epilepsy submitted to surgery: A case-control study. *Eur J Neurol*. 2023 Oct;30(10):2999–3007. doi: 10.1111/ene.15963. (Impact Factor 5.1)
 18. Curatolo P, Scheper M, Emberti Gialloreti L, Specchio N, **Aronica E**. Is tuberous sclerosis complex-associated autism a preventable and treatable disorder? *World J Pediatr*. 2023 Oct 25. doi: 10.1007/s12519-023-00762-2. Online ahead of print. PMID: 37878130 Review. (Impact Factor 8.7)
 19. Devine JK, Schwartz L, Hursh S, Asin J, de Vries N, Vonk PE, Vermeeren A, **Donjacour CEHM**, Vinckenbosch F, Ramaekers JG, Janssen H, Wang G, Chen D, Carter LP, Overeem S, **Lammers GJ**. Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions. *Neurol Ther*. 2023 Feb;12(1):249–265. doi: 10.1007/s40120-022-00425-w. (Impact Factor 3.7)
 20. Dauvilliers Y, **Lammers GJ**, Lecendreux M, Maski K, Kansagra S, Black J, Parvataneni R, Chen A, Wang YG, Plazzi G. Effect of sodium oxybate on body mass index in pediatric patients with narcolepsy. *J Clin Sleep Med*. 2023 Nov 9. doi: 10.5664/jcsm.10912. Online ahead of print. PMID: 37942930 (Impact Factor 4.3)
 21. van Dijk JG, Gagaouzova BS, van Houwelingen MJ, Reijntjes RHAM, Kerkhof FI, van Rossum IA, **Thijs RD**. A case showing how hyperventilation may decrease blood pressure in neurogenic orthostatic hypotension. *Clin Auton Res*. 2023 Aug;33(4):549–552. doi: 10.1007/s10286-023-00964-8. (Impact Factor 5.8)

22. van Dijk JG, van Rossum IA, van Waning JI, Westra SW, **Thijs RD**. Clinical signs of the transition of syncope into hypoxic coma: a case report. *Clin Auton Res*. 2023 Dec;33(6):915–918. doi: 10.1007/s10286-023-00978-2. (Impact Factor 5.8)
23. Dimitriades ME, Markovic A, **Gefferie SR**, Buckley A, Driver DI, Rapoport JL, Nosadini M, Rostasy K, Sartori S, Suppiej A, Kurth S, Franscini M, Walitza S, Huber R, Tarokh L, Bölsterli BK, Gerstenberg M. Sleep spindles across youth affected by schizophrenia or anti-*N*-methyl-D-aspartate-receptor encephalitis. *Front Psychiatry*. 2023 Jun 7;14:1055459. doi: 10.3389/fpsyt.2023.1055459. PMID: 37377467 (Impact Factor 4.7)
24. Fanciulli A, Leys F, Krbot Skorić M, Carneiro DR, Calandra-Buonaura G, Camaradou J, Chiaro G, Cortelli P, Falup-Pecurariu C, Granata R, Guaraldi P, Helbok R, Hilz MJ, Iodice V, Jordan J, Kaal ECA, Kamondi A, Pavy Le Traon A, Rocha I, Sellner J, Senard JM, Terkelsen A, Wenning GK, Moro E, Berger T, **Thijs RD**, Struhal W, Habek M; Collaborators of European Network of Neurological ANS laboratories. Impact of the COVID-19 pandemic on clinical autonomic practice in Europe A survey of the European Academy of Neurology (EAN) and the European Federation of Autonomic Societies (EFAS). *Eur J Neurol*. 2023 Mar 15. doi: 10.1111/ene.15787. Online ahead of print. PMID: 36920252 (Impact Factor 5.1)
25. Fanciulli A, Skorić MK, Leys F, Carneiro DR, Campese N, Calandra-Buonaura G, Camaradou J, Chiaro G, Cortelli P, Falup-Pecurariu C, Granata R, Guaraldi P, Helbok R, Hilz MJ, Iodice V, Jordan J, Kaal ECA, Kamondi A, Le Traon AP, Rocha I, Sellner J, Senard JM, Terkelsen A, Wenning GK, Moro E, Berger T, **Thijs RD**, Struhal W, Habek M; Collaborators of European Network of Neurological Autonomic Laboratories. EFAS/EAN survey on the influence of the COVID-19 pandemic on European clinical autonomic education and research. *Clin Auton Res*. 2023 Dec;33(6):777–790. doi: 10.1007/s10286-023-00985-3. (Impact Factor 5.8)
26. Ferreira-Atuesta C, de Tisi J, McEvoy AW, Miserocchi A, Khoury J, Yardi R, Vegh DT, Butler J, Lee HJ, Deli-Peri V, Yao Y, Wang FP, Zhang XB, Shakhathreh L, Siriratnam P, Neal A, Sen A, Tristram M, Varghese E, Biney W, Gray WP, Peralta AR, Rainha-Campos A, Gonçalves-Ferreira AJC, Pimentel J, Arias JF, Terman S, Terziev R, Lamberink HJ, Braun KPJ, Otte WM, Rugg-Gunn FJ, Gonzalez W, Bentes C, Hamandi K, O'Brien TJ, Perucca P, Yao C, Burman RJ, Jehi L, Duncan JS, **Sander JW**, Koepp M, Galovic M. Predictive models for starting antiseizure medication withdrawal following epilepsy surgery in adults. *Brain*. 2023 Jun 1;146(6):2389–2398. doi: 10.1093/brain/awac437. PMID: 36415957 (Impact Factor 14.5)
27. Frauscher B, Bénar CG, Engel JJ, Grova C, Jacobs J, Kahane P, Wiebe S, **Zijlmans M**, Dubeau F. Neurophysiology, Neuropsychology, and Epilepsy, in 2022: Hills We Have Climbed and Hills Ahead. *Neurophysiology in epilepsy*. *Epilepsy Behav*. 2023 Jun;143:109221. doi: 10.1016/j.yebeh.2023.109221 (Impact Factor 2.6)
28. Frauscher B, Mansilla D, Abdallah C, Astner-Rohracher A, Beniczky S, Brazdil M, Gnatkovsky V, Jacobs J, Kalamangalam G, Perucca P, Ryvlin P, Schuele S, Tao J, Wang Y, **Zijlmans GJM**, McGonigal A. Learn how to interpret and use intracranial EEG findings. *Epileptic Disord*. 2023 Dec 20. doi: 10.1002/epd2.20190. Online ahead of print. (Impact Factor 2.3)
29. **Gefferie SR**, Jiménez-Jiménez D, **Visser GH**, **Helling RM**, **Sander JW**, Balestrini S, **Thijs RD**. Transcranial magnetic stimulation-evoked electroencephalography responses as biomarkers for epilepsy: A review of study design and outcomes. *Hum Brain Mapp*. 2023 Jun 1; 44(8): 3446–3460. (Impact Factor 4.8)
30. Ghariq M, van den Hout WB, Dekkers OM, **Bootsma M**, de Groot B, Groothuis JGJ, Harms MPM, Hemels MEW, Kaal ECA, Koomen EM, de Lange FJ, Peeters SYG, van Rossum IA, Rutten JHW, van Zwet EW, van Dijk JG, **Thijs RD**; SYNERGY Consortium. Diagnostic and societal impact of implementing the syncope guidelines of the European Society of Cardiology (SYNERGY study). *BMC Med*. 2023 Sep 25;21(1):365. doi: 10.1186/s12916-023-03056-6. PMID: 37743496 (Impact Factor 9.3)

31. **Gool JK**, van Heese EM, Schinkelshoek MS, Remmerswaal A, **Lammers GJ**, **van Dijk KD**, **Fronczek R**. The therapeutic potential of opioids in narcolepsy type 1: A systematic literature review and questionnaire study. *Sleep Med.* 2023 Sep;109:118–127. doi: 10.1016/j.sleep.2023.06.008. (Impact Factor 4.8)
32. **Gool JK**, **Schinkelshoek MS**, **Fronczek R**. What triggered narcolepsy: H1N1 vaccination, virus, or both? Important lessons learned from China. *Sleep.* 2023 Mar 9;46(3):zsad005. doi: 10.1093/sleep/zsad005. PMID: 36629301 (Impact Factor 5.6)
33. Hadders–Algra M, van Iersel PAM, **Heineman KR**, la Bastide–van Gemert S. Longer duration of gestation in term singletons is associated with better infant neurodevelopment. *Early Hum Dev.* 2023 Jun;181:105779. doi: 10.1016/j.earlhumdev.2023.105779. (Impact Factor 2.5)
34. **Hagebeuk EEO**, **Smits A**, **de Weerd A**. Long time polysomnographic sleep and breathing evaluations in children with CDKL5 deficiency disorder. *Sleep Med.* 2023 Mar;103:173–179. doi: 10.1016/j.sleep.2023.02.003. (Impact Factor 4.8)
35. Hanin A, Cespedes J, Huttner A, Strelnikov D, Gopaul M, DiStasio M, Vezzani A, Hirsch LJ, **Aronica E**. Neuropathology of New–Onset Refractory Status Epilepticus (NORSE). *J Neurol.* 2023 Aug;270(8):3688–3702. doi: 10.1007/s00415–023–11726–x. PMID: 37079033 (Impact Factor 6)
36. Hanin, A; Cespedes, J; Pulluru, Y; Gopaul, M; **Aronica, E**; Decampo, D; Helbig, I; Howe, C; Huttner, A; Koh, S; Navarro, V; Taraschenko, O; Vezzani, A; Wilson, M; Xian, J; Gaspard, N; Hirsch, L. Review and standard operating procedures for collection of biospecimens and analysis of biomarkers in New–Onset Refractory Status Epilepticus (NORSE). *Epilepsia*, doi: 10.1111/epi.17600, 2023. (Impact Factor 5.6)
37. Heiskanen M, Das Gupta S, Mills JD, van Vliet EA, Manninen E, Cizek R, Andrade P, Puhakka N, **Aronica E**, Pitkänen A. Discovery and Validation of Circulating microRNAs as Biomarkers for Epileptogenesis after Experimental Traumatic Brain Injury–The EPITARGET Cohort. *Int J Mol Sci.* 2023 Feb 1;24(3):2823. doi: 10.3390/ijms24032823. PMID: 36769143 (Impact Factor 5.6)
38. **Helling RM**, Perenboom MJL, Bauer PR, Carpay JA, **Sander JW**, Ferrari MD, **Visser GH**, Tolner EA. TMS–evoked EEG potentials demonstrate altered cortical excitability in migraine with aura. *Brain Topogr.* 2023 Mar;36(2):269–281. doi: 10.1007/s10548–023–00943–2. (Impact Factor 2.7)
39. Hepp DH, van Wageningen TA, Kuiper KL, **van Dijk KD**, Oosterveld LP, Berendse HW, van de Berg WDJ. Inflammatory Blood Biomarkers Are Associated with Long–Term Clinical Disease Severity in Parkinson's Disease. *Int J Mol Sci.* 2023 Oct 5;24(19): 14915. doi: 10.3390/ijms241914915. PMID: 37834363 (Impact Factor 5.6)
40. Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffiatti R, Wick W, Chinot O, Ducray F, Roth P, McDonald K, Hau P, Hottinger AF, Reijneveld J, Schnell O, Marosi C, Glantz M, Darlix A, Lombardi G, Krex D, Glas M, Reardon DA, van den Bent M, Lefranc F, Herrlinger U, Razić E, Carpentier AF, Phillips S, Rudà R, Wick A, Tabouret E, Meyronet D, Maurage CA, Rushing E, Rapkins R, Bumès E, Hegi M, **Weyerbrock A**, Aregawi D, Gonzalez–Gomez C, Pellerino A, Klein M, Preusser M, Bendszus M, Golfinopoulos V, von Deimling A, Gorlia T, Wen PY, Reifenberger G, Weller M. Long–term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419). *Eur J Cancer.* 2023 Aug;189:112913 doi: 10.1016/j.ejca.2023.05.002. PMID: 37277265 (Impact Factor 8.4)
41. **van der Hoeven AE**, **Bijlenga D**, Bouhuijs P, van Schie MKM, **Lammers GJ**, **Fronczek R**. Applicability of the Sustained Attention to Response Task (SART) in hypersomnolence: Experience and results from a tertiary referral center. *Sleep Med.* 2023 Aug;108:105–113. doi: 10.1016/j.sleep.2023.06.007. (Impact Factor 4.8)
42. van Hugte EJH, Lewerissa EI, Wu KM, Scheefhals N, Parodi G, van Voorst TW, Puvogel S, Kogo N, Keller JM, Frega M, Schubert D, **Schelhaas HJ**, Verhoeven J, Majoie M, van Bokhoven H, Nadif

- Kasri N. SCN1A-deficient excitatory neuronal networks display mutation-specific phenotypes. *Brain*. 2023 Dec 1;146(12):5153–5167. doi: 10.1093/brain/awad245. PMID: 37467479 (Impact Factor 14.5)
43. Huschner F, Głowacka-Walas J, Mills JD, Klonowska K, Lasseter K, Asara JM, Moavero R, Hertzberg C, Weschke B, Riney K, Feucht M, Scholl T, Krsek P, Nabbout R, Jansen AC, Petrák B, van Scheppingen J, Zamecnik J, Iyer A, Anink JJ, Mühlebner A, Mijnsbergen C, Lagae L, Curatolo P, Borkowska J, Sadowski K, Domańska-Pakieła D, Blazejczyk M, Jansen FE, Janson S, Urbanska M, Tempes A, Janssen B, Sijko K, Wojdan K, Jozwiak S, Kotulska K, Lehmann K, **Aronica E**, Jaworski J, Kwiatkowski DJ. Molecular EPISTOP, a comprehensive multi-omic analysis of blood from Tuberous Sclerosis Complex infants age birth to two years. *Nat Commun*. 2023 Nov 23;14(1):7664. doi: 10.1038/s41467-023-42855-6. PMID: 37996417 (Impact Factor 16.6)
 44. **Janssens K**, **Amesz P**, **Nuvelstijn Y**, **Donjacour C**, **Hendriks D**, Peeters E, Quaedackers L, Vandebussche N, **Pillen S**, **Lammers GJ**. School Problems and School Support for Children with Narcolepsy: Parent, Teacher, and Child Reports. *Int J Environ Res Public Health*. 2023 Mar 15;20(6):5175. doi: 10.3390/ijerph20065175. PMID: 36982084 (Impact Factor unknown)
 45. Jones GD, Kariuki SM, Ngugi AK, Mwesige AK, Masanja H, Owusu-Agyei S, Wagner R, Cross JH, **Sander JW**, Newton CR, Sen A; EPIInA Study Group. Development and validation of a diagnostic aid for convulsive epilepsy in sub-Saharan Africa: a retrospective case-control study. *Lancet Digit Health*. 2023 Apr;5(4):e185–e193. doi: 10.1016/S2589-7500(22)00255-2. PMID: 36963908 (Impact Factor 30.8)
 46. de Jong JSY, van Zanten S, **Thijs RD**, van Rossum IA, Harms MPM, de Groot JR, Sutton R, de Lange FJ. Syncope Diagnosis at Referral to a Tertiary Syncope Unit: An in-Depth Analysis of the FAST II. *J Clin Med*. 2023 Apr 12(7):2562. (Impact Factor 3.9)
 47. **Kalitzin S**. Adaptive Remote Sensing Paradigm for Real-Time Alerting of Convulsive Epileptic Seizures. *Sensors (Basel)*. 2023 Jan 14;23(2):968. doi: 10.3390/s23020968. PMID: 36679763 (Impact Factor 3.9)
 48. Kariuki SM, Wagner RG, Gunny R, D'Arco F, Kombe M, Ngugi AK, White S, Odhiambo R, Cross JH, **Sander JW**, Newton CRJC. Magnetic Resonance Imaging Findings in Kenyans and South Africans with Active Convulsive Epilepsy: An Observational Study. *Epilepsia*. 2024 Jan;65(1):165–176 doi: 10.1111/epi.17829. PMID: 37964464. (Impact Factor 5.6)
 49. Kasradze S, Gogatishvili N, Lazariashvili M, Lomidze G, **Sander JW**. Validation of the Georgian version of a Stigma Scale of Epilepsy. *Epilepsy Behav*. 2023 Nov;148:109502. doi: 10.1016/j.yebeh.2023.109502. PMID: 37897863 (Impact Factor 2.6)
 50. **Keezer MR**, Bauer PR, **Sander JW**. The Future: Moving from Phenotypically Defined Diseases Toward Pathophysiological Systems. *Can J Neurol Sci*. 2023 Mar 1:1–3. doi: 10.1017/cjn.2023.30. Online ahead of print. PMID: 36855937 (Impact Factor unknown)
 51. Kim JH, Park JH, Lee J, Park JW, Kim HJ, Chang WS, Kim DS, Ju YS, **Aronica E**, Lee JH. Ultra-Low Level Somatic Mutations and Structural Variations in Focal Cortical Dysplasia Type II. *Ann Neurol*. 2023 Jun;93(6):1082–1093 doi: 10.1002/ana.26609. PMID: 36700525 (Impact Factor 11.2)
 52. Laskier V, Agyei-Kyeremateng KK, Eddy AE, Patel D, Mulheron S, James S, Thomas RH, **Sander JW**. Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy. *Epilepsia*. 2023 Apr;64(4):843–856. doi: 10.1111/epi.17506. PMID: 36625423 (Impact Factor 5.6)
 53. van Leeuwen MMA, Droger MM, **Thijs RD**, Kuijper B. Nocturnal seizure detection: What are the needs and expectations of adults with epilepsy receiving secondary care? *Epilepsy Behav*. 2023 Oct;147:109398 doi: 10.1016/j.yebeh.2023.109398. PMID: 37666205 (Impact Factor 2.6)

54. Leitner, D; Lin, Z; Sawaged, Z; Kanshin, E; Friedman, D; Devore, S; Ueberheide, B; Chang, J; Mathern, G; Anink, J; **Aronica, E**; Wisniewski, T; Devinsky, O. Brain Molecular Mechanisms in Rasmussen Encephalitis Leitner, Dominique;. *Epilepsia*, doi: 10.1111/epi.17457, 64(1):218–230, 2023 (Impact Factor 5.6)
55. Lemoine É, Neves Briard J, Rioux B, Podbielski R, Nauche B, Toffa D, **Keezer M**, Lesage F, Nguyen DK, Bou Assi E. Computer-assisted analysis of routine electroencephalogram to identify hidden biomarkers of epilepsy: protocol for a systematic review. *BMJ Open*. 2023 Jan 24;13(1):e066932. doi: 10.1136/bmjopen-2022-066932. PMID: 36693684 (Impact Factor 2.9)
56. Lemoine É, Neves Briard J, Rioux B, Gharbi O, Podbielski R, Nauche B, Toffa D, **Keezer M**, Lesage F, Nguyen DK, Bou Assi E. Computer-assisted analysis of routine EEG to identify hidden biomarkers of epilepsy: A systematic review. *Comput Struct Biotechnol J*. 2023 Dec 10;24:66–86. doi: 10.1016/j.csbj.2023.12.006. eCollection 2024 Dec. PMID: 38204455 (Impact Factor 6)
57. van Lingen MR, Breedt LC, Geurts JJG, Hillebrand A, Klein M, Kouwenhoven MCM, Kulik SD, **Reijneveld JC**, Stam CJ, De Witt Hamer PC, Zimmermann MLM, Santos FAN, Douw L. The longitudinal relation between executive functioning and multilayer network topology in glioma patients. *Brain Imaging Behav*. 2023 Aug;17(4):425–435 doi: 10.1007/s11682-023-00770-w. PMID: 37067658 (Impact Factor 3.2)
58. Lu L, Chen L, Wang P, Qi Z, Chen Y, Wu X, Liu X, Wang M, Li J, Yan B, Guo J, Teng S, Li W, **Sander JW**, Zhou D, Xiong W. Neurological complications during the Omicron COVID-19 wave in China: A cohort study. *Eur J Neurol*. 2024 Jan;31(1):e16096. doi: 10.1111/ene.16096. PMID: 37877685 (Impact Factor 5.1)
59. Luinenburg MJ, Scheper M, Sørensen FNF, Anink JJ, Van Hecke W, Korshunova I, Jansen FE, Riney K, van Eijsden P, Gosselaar P, Mills JD, Kalf RS, Zimmer TS, Broekaart DWM, Khodosevich K, **Aronica E**, Mühlebner A. Loss of maturity and homeostatic functions in Tuberous Sclerosis Complex-derived astrocytes. *Front Cell Neurosci*. 2023 Nov 28;17:1284394. doi: 10.3389/fncel.2023.1284394. eCollection 2023. PMID: 38089143 (Impact Factor 5.3)
60. Lund NLT, Petersen AS, **Fronczek R**, Tfelt-Hansen J, Belin AC, Meisingset T, Tronvik E, Steinberg A, Gaul C, Jensen RH. Current treatment options for cluster headache: limitations and the unmet need for better and specific treatments—a consensus article. *J Headache Pain*. 2023 Sep 4;24(1):121. doi: 10.1186/s10194-023-01660-8. PMID: 37667192 (Impact Factor 7.4)
61. Monahan RC, Middelkoop HAM, Beaart-van de Voorde LJJ, **Fronczek R**, Groenwold RHH, Kloppenburg M, Huizinga TWJ, Steup-Beekman GM. High Prevalence but Low Impact of Cognitive Dysfunction on Quality of Life in Patients With Lupus and Neuropsychiatric Symptoms. *Arthritis Care Res (Hoboken)*. 2023 May;75(5):1017–1025. doi: 10.1002/acr.24904. Epub 2022 Dec 12. PMID: 35470979 (Impact Factor 5.2)
62. Monahan RC, Beaart-van de Voorde LJJ, **Fronczek R**, de Bresser J, Eikenboom J, Kloppenburg M, Middelkoop HAM, Terwindt GM, van der Wee NJA, Huizinga TWJ, Steup-Beekman GM. Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study. *Lupus Sci Med*. 2023 Feb;10(1):e000850. doi: 10.1136/lupus-2022-000850. PMID: 36737098 (Impact Factor 3.9)
63. Naber WC, Brandt RB, Figetakis DD, Jahanshahi M, Terwindt GM, **Fronczek R**. Translating the Cluster Headache Quality of Life Questionnaire (CHQ) from English to Dutch with the TRAPD method. *Neurol Sci*. 2023 Oct 6. doi: 10.1007/s10072-023-07088-x. Online ahead of print. PMID: 37801235 (Impact Factor 3.3)
64. Ollila HM, Sharon E, Lin L, Sinnott-Armstrong N, Ambati A, Yogeshwar SM, Hillary RP, Jolanki O, Faraco J, Einen M, Luo G, Zhang J, Han F, Yan H, Dong XS, Li J, Zhang J, Hong SC, Kim TW,

- Dauvilliers Y, Barateau L, **Lammers GJ**, **Fronczek R**, Mayer G, Santamaria J, Arnulf I, Knudsen-Heier S, Bredahl MKL, Thorsby PM, Plazzi G, Pizza F, Moresco M, Crowe C, Van den Eeden SK, Lecendreux M, Bourgin P, Kanbayashi T, Martínez-Orozco FJ, Peraita-Adrados R, Benetó A, Montplaisir J, Desautels A, Huang YS; FinnGen; Jennum P, Nevsimalova S, Kemlink D, Iranzo A, Overeem S, Wierzbicka A, Geisler P, Sonka K, Honda M, Högl B, Stefani A, Coelho FM, Mantovani V, Feketeova E, Wadelius M, Eriksson N, Smedje H, Hallberg P, Hesla PE, Rye D, Pelin Z, Ferini-Strambi L, Bassetti CL, Mathis J, Khatami R, Aran A, Nampoothiri S, Olsson T, Kockum I, Partinen M, Perola M, Kornum BR, Rueger S, Winkelmann J, Miyagawa T, Toyoda H, Khor SS, Shimada M, Tokunaga K, Rivas M, Pritchard JK, Risch N, Kutalik Z, O'Hara R, Hallmayer J, Ye CJ, Mignot EJ. Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy. *Nat Commun.* 2023 May 15;14(1):2709. doi: 10.1038/s41467-023-36120-z.PMID: 37188663 (Impact Factor 16.6)
65. Palma JA, **Thijs RD**. Non-Pharmacological Treatment of Autonomic Dysfunction in Parkinson's Disease and Other Synucleinopathies. *J Parkinsons Dis.* 2023 Sep 7. doi: 10.3233/JPD-230173. Online ahead of print.PMID: 37694308 (Impact Factor 5.2)
66. Peltola J, Colon AJ, Pimentel J, Coenen VA, Gil-Nagel A, Ferreira AG, Lehtimäki K, Ryvlin P, Taylor RS, Ackermans L, **Ardesch J**, Bentes C, Bosak M, Burneo JG, Chamadoira C, Elger CE, Erőss L, Fabo D, Faulkner H, Gawlowicz J, Gharabaghi A, Iacoangeli M, Janszky J, Järvenpää S, Kaufmann E, Kho KH, Kumlien E, Laufs H, Lettieri C, Linhares P, Noachtar S, Parrent A, Pataria E, Patel NK, Peralta AR, Rácz A, Campos AR, Rego R, Ricciuti RA, Rona S, Rouhl RPW, Schulze-Bonhage A, Schuurman R, Sprengers M, Sufianov A, Temel Y, Theys T, Van Paesschen W, Van Roost D, Vaz R, Vonck K, Wagner L, **Zwemmer J**, Abouihia A, Brionne TC, Gielen F, Boon PAJM. Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Drug Resistant Epilepsy in the MORE Multicenter Patient Registry. *Neurology.* 2023 May 2;100(18):e1852–e1865 doi: 10.1212/WNL.0000000000206887. PMID: 36927882 (Impact Factor 9.9)
67. Plazzi G, Pizza F, Lecendreux M, Gringras P, Barateau L, Bruni O, Franco P, Iranzo A, Jennum P, Khatami R, Knudsen-Heier S, Miano S, Nobili L, Partinen M, Reading P, Sonka K, Szakacs A, Zenti M, Kallweit U, **Lammers GJ**, Dauvilliers Y, Bassetti CLA. Pharmacological management of narcolepsy in children and adolescents. *J Sleep Res.* 2023 Dec 4:e14055. doi: 10.1111/jsr.14055. Online ahead of print.PMID: 38050449 (Impact Factor 4.4)
68. Quaedackers L, Van Gilst MM, Van Den Brandt I, Vilanova A, **Lammers GJ**, Markopoulos P, Overeem S. The Burden of Narcolepsy in Adults: A Population Sampling Study Using Personal Media. *Behav Sleep Med.* 2023 May 29:1–11. doi: 10.1080/15402002.2023.2217971. Online ahead of print.PMID: 37246794 (Impact Factor 4.8)
69. **Reijneveld JC**, Machingura A, Coens C, Taphoorn MJB, Taal W, Clement PM, Idbaih A, de Vos FYF, Klein M, Wick W, Mulholland PJ, Lewis J, Golfopoulos V, Ghislain I, Bottomley A, van den Bent MJ; Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091). EORTC Brain Tumor Group. *Eur J Cancer.* 2023 Sep;190:112946. doi: 10.1016/j.ejca.2023.112946. (Impact Factor 8.4)
70. **Reus EEM**, **Visser GH**, Sommers-Spijkerman MPJ, van Dijk JG, **Cox FME**. Automated spike and seizure detection: Are we ready for implementation? *Seizure.* 2023 May;108:66–71. doi: 10.1016/j.seizure.2023.04.010. (Impact Factor 3)
71. Rogge AA, Petersen MA, Aaronson NK, Conroy T, Dirven L, Fischer F, Habets E, **Reijneveld JC**, Rose M, Sleurs C, Taphoorn M, Tomaszewski KA, Vachon H, Young T, Groenvold M; EORTC Quality of Life Group. Development and psychometric evaluation of item banks for memory and attention – supplements to the EORTC CAT Core instrument. *Health Qual Life Outcomes.* 2023 Nov 15;21(1):124. doi: 10.1186/s12955-023-02199-7.PMID: 37968682 (Impact Factor 3.6)

72. van Rootselaar AF, Coccozza S, **Aronica E**, Striano P. Familial adult myoclonus epilepsy: Neuroimaging and neuropathological findings. *Epilepsia*. 2023 Jun;64 Suppl 1:S47–S51. doi: 10.1111/epi.17628. (Impact Factor 5.6)
73. van Rossum IA, de Lange FJ, Benditt DG, van Zwet EW, van Houwelingen M, **Thijs RD**, van Dijk JG. Variability of cardioinhibition in vasovagal syncope: differences between subgroups during cardioinhibition and beyond. *Clin Auton Res*. 2023 Dec;33(6):749–755. doi: 10.1007/s10286-023-00991-5. PMID: 37874434 (Impact Factor 5.8)
74. Röttgering JG, Varkevisser TMCK, Gorter M, Belgers V, De Witt Hamer PC, **Reijneveld JC**, Klein M, Blanken TF, Douw L. Symptom networks in glioma patients: understanding the multidimensionality of symptoms and quality of life. *J Cancer Surviv*. 2023 Mar 16. doi: 10.1007/s11764-023-01355-8. Online ahead of print. PMID: 36922442 (Impact Factor 3.7)
75. **Schelhaas M**, **Wegner I**, Edens M, Wammes–Van Der Heijden E, Touw D, Ter Horst P. Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy. *Neurology*. 2023 Jan 10;100(2):e172–e181. doi: 10.1212/WNL.0000000000201348. (Impact Factor 9.9)
76. **Schinkelshoek MS**, **Fronczek R**, **de Boer AFJ**, de Wit K, Tannemaat MR, **Lammers GJ**. Warm ears, a red flag for sleepiness? *J Sleep Res*. 2023 Apr;32(2):e13707. doi: 10.1111/jsr.13707. (Impact Factor 4.4)
77. Seifinejad A, Ramosaj M, Shan L, Li S, Possovre ML, Pfister C, **Fronczek R**, Garrett–Sinha LA, Frieser D, Honda M, Arribat Y, Grepper D, Amati F, Picot M, Agnoletto A, Iseli C, Chartrel N, Liblau R, **Lammers GJ**, Vassalli A, Tafti M. Epigenetic silencing of selected hypothalamic neuropeptides in narcolepsy with cataplexy. *Proc Natl Acad Sci U S A*. 2023 May 9;120(19):e222091120. doi: 10.1073/pnas.222091120. (Impact Factor 11.1)
78. Shan L, Linssen S, Harteman Z, den Dekker F, Shuker L, Balesar R, Breesuwsma N, Anink J, Zhou J, **Lammers GJ**, Swaab DF, **Fronczek R**. Activated Wake Systems in Narcolepsy Type 1. *Ann Neurol*. 2023 Oct;94(4):762–771. (Impact Factor 11.2)
79. Shen S, Dong Z, **Sander JW**, Zhou D, Li J. Somatic symptoms and related disorders in a large cohort of people with epilepsy: A cohort study. *Epilepsia*. 2023 Feb;64(2):320–334. doi: 10.1111/epi.17453. (Impact Factor 5.6)
80. Singh G, **Sander JW**. The case for levetiracetam to be included in essential medicine lists. *Lancet Reg Health Southeast Asia*. 2023 Jun 1;14:100211. doi: 10.1016/j.lansea.2023.100211. (Impact Factor unknown)
81. Singh G, Singh MB, Ding D, Maulik P, **Sander JW**. Implementing WHO's Intersectoral Global Action Plan for **epilepsy** and other neurological disorders in Southeast Asia: a proposal. *Lancet Reg Health Southeast Asia*. 2023 Mar;10:100135. doi: 10.1016/j.lansea.2022.100135. PMID: 37197018 (Impact Factor unknown)
82. Sinka L, Abaira L, Imbach LL, Zieglgänsberger D, Santamarina E, Álvarez–Sabín J, Ferreira–Atuesta C, Katan M, Scherrer N, Biciato G, Terziev R, Simmen C, Schubert KM, Elshahabi A, Baumann CR, Döhler N, Erdélyi–Canavese B, Felbecker A, Siebel P, Winklehner M, von Oertzen TJ, Wagner JN, Gigli GL, Serafini A, Nilo A, Janes F, Merlino G, Valente M, Zafra–Sierra MP, Bayona–Ortiz H, Conrad J, Evers S, Lochner P, Roell F, Brigo F, Bentes C, Peralta AR, Pinho E Melo T, **Keezer MR**, Duncan JS, **Sander JW**, Tettenborn B, Koepp MJ, Galovic M. Association of Mortality and Risk of Epilepsy With Type of Acute Symptomatic Seizure After Ischemic Stroke and an Updated Prognostic Model. *JAMA Neurol*. 2023 Jun 1;80(6):605–613. doi: 10.1001/jamaneurol.2023.0611. PMID: 37036702 (Impact Factor 29)
83. Slinger G, Noorlag L, van Diessen E, Otte WM, **Zijlmans M**, Jansen FE, Braun KPJ. Clinical characteristics and diagnoses of 1,213 children referred to a first seizure clinic. *Epilepsia Open*. 2023 Dec 15. doi: 10.1002/epi4.12883. Online ahead of print. PMID: 38101810 (Impact Factor 3)

84. Specchio N, Nabbout R, **Aronica E**, Auvin S, Benvenuto A, de Palma L, Feucht M, Jansen F, Kotulska K, Sarnat H, Lagae L, Jozwiak S, Curatolo P. Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy. *Eur J Paediatr Neurol*. 2023 Nov;47:25–34. doi: 10.1016/j.ejpn.2023.08.005.PMID: 37669572 (Impact Factor 3.1)
85. van der Stam AH, **Shmuely S**, de Vries NM, Bloem BR, **Thijs RD**. The Impact of Head-Up Tilt Sleeping on Orthostatic Tolerance: A Scoping Review. *Biology (Basel)*. 2023 Aug 9;12(8):1108. doi: 10.3390/biology12081108.PMID: 37626994 (Impact Factor 4.2)
86. Stefanski A, Pérez–Palma E, Brünger T, Montanucci L, Gati C, Klöckner C, Johannesen KM, Goodspeed K, Macnee M, Deng AT, Aledo–Serrano Á, Borovikov A, Kava M, Bouman AM, Hajianpour MJ, Pal DK, Engelen M, **Hagebeuk EEO**, Shinawi M, Heidlebaugh AR, Oetjens K, Hoffman TL, Striano P, Freed AS, Futtrup L, Balslev T, Abulí A, Danvoye L, Lederer D, Balci T, Nabavi Nouri M, Butler E, Drewes S, van Engelen K, Howell KB, Khoury J, May P, Trinidad M, Froelich S, Lemke JR, Tiller J, Freed AN, Kang JQ, Wuster A, Møller RS, Lal D. SLC6A1 variant pathogenicity, molecular function, and phenotype: a genetic and clinical analysis. *Brain*. 2023 Dec 1;146(12):5198–5208. doi: 10.1093/brain/awad292. PMID: 37647852 (Impact Factor 14.5)
87. Straka B, Splitkova B, Vlckova M, Tesner P, Rezacova H, Krskova L, Koblizek M, Kyncl M, Maulisova A, Bukacova K, Uhrova–Meszarosova A, Musilova A, Kudr M, Ebel M, Belohlavkova A, Jahodova A, Liby P, Tichy M, Jezdik P, Zamecnik J, **Aronica E**, Krsek P. Genetic testing in children enrolled in epilepsy surgery program. A real–life study. *Eur J Paediatr Neurol*. 2023 Nov;47:80–87. doi: 10.1016/j.ejpn.2023.09.009. PMID: 37812946 (Impact Factor 3.1)
88. Sullivan J, **Gunning B**, Zafar M, Guerrini R, Gecz J, Kolc KL, Zhao Y, Gasior M, Aimetti AA, Samanta D. Phase 2, placebo–controlled clinical study of oral ganaxolone in PCDH19–clustering epilepsy. *Epilepsy Res*. 2023 Mar;191:107112. doi: 10.1016/j.eplepsyres.2023.107112. (Impact Factor 2.2)
89. Terman SW, Slinger G, Koek A, Skvarce J, Springer MV, Ziobro JM, Burke JF, **Otte WM**, **Thijs RD**, Braun KPJ. Frequency of and factors associated with antiseizure medication discontinuation discussions and decisions in patients with epilepsy: A multicenter retrospective chart review. *Epilepsia Open*. 2023 Jun; 8(2): 371–385 (Impact Factor 3)
90. Terman SW, **van Griethuysen R**, Rheume CE, Slinger G, Haque AS, Smith SN, Kerr WT, **van Asch C**, **Otte WM**, Ferreira–Atuesta C, Galovic M, Burke JF, Braun KPJ. Antiseizure medication withdrawal risk estimation and recommendations: A survey of American Academy of Neurology and EpiCARE members. *Epilepsia Open*. 2023 Feb;13(1):e200109. doi: 10.1002/epi4.12696. PMID: 36721311 (Impact Factor 3)
91. Terman SW, Slinger G, Koek A, Skvarce J, Springer MV, Ziobro JM, Burke JF, **Otte WM**, **Thijs RD**, Lossius MI, Marson AG, Bonnett LJ, Braun KP. Variation in seizure risk increase from antiseizure medication withdrawal among patients with well–controlled epilepsy: a pooled analysis. *Epilepsia Open*. 2023 Dec 10. doi: 10.1002/epi4.12880. Online ahead of print.PMID: 38071463 (Impact Factor 3)
92. **Thijs RD**, Fedorowski A. How to unblur the vasovagal evidence? *Clin Auton Res*. 2023 Feb;33(1):5–7. doi: 10.1007/s10286–022–00915–9. (Impact Factor 5.8)
93. **Thijs RD**, Raj SR. How low can you go: heart rate dynamics in between vasovagal syncope. *Clin Auton Res*. 2023 Dec 23. doi: 10.1007/s10286–023–01005–0. Online ahead of print.PMID: 38141132. (Impact Factor 5.8)
94. Tveit J, Aurlien H, Plis S, Calhoun VD, Tatum WO, Schomer DL, Arntsen V, **Cox F**, Fahoum F, Gallentine WB, Gardella E, Hahn CD, Husain AM, Kessler S, Kural MA, Nascimento FA, Tankisi H, Ulvin LB, Wennberg R, Beniczky S. Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence. *JAMA Neurol*. 2023 Aug 1;80(8):805–812. doi: 10.1001/jamaneurol.2023.1645. PMID: 37338864 (Impact Factor 29)

95. **Vael VEC, Bijlenga D**, Schinkelshoek MS, van der Sluiszen NNJM, Remmerswaal A, Overeem S, Ramaekers JG, Vermeeren A, **Lammers GJ, Fronczek R**. Skin temperature as a predictor of on-the-road driving performance in people with central disorders of hypersomnolence. *J Sleep Res.* 2023 Sep 18:e14045. doi: 10.1111/jsr.14045. Online ahead of print. PMID: 37720977 (Impact Factor 4.4)
96. Verhoeff MC, Koutris M, Vries R, Berendse HW, **Dijk KDV**, Lobbezoo F. Salivation in Parkinson's disease: A scoping review. *Gerodontology.* 2023 Mar;40(1):26–38. doi: 10.1111/ger.12628. (Impact Factor 2)
97. Verhoeff MC, Eikenboom D, Koutris M, de Vries R, Berendse HW, **van Dijk KD**, Lobbezoo F. Parkinson's disease and oral health: A systematic review. *Arch Oral Biol.* 2023 Jul;151:105712. doi: 10.1016/j.archoralbio.2023.105712. (Impact Factor 3)
98. Verhoeff MC, Thymi M, Brandwijk AN, Heres MS, Koutris M, Berendse HW, **van Dijk KD**, Lobbezoo F. Clinicians' view on the management of oral health in Parkinson's disease patients: a qualitative study. *BDJ Open.* 2023 May 12;9(1):20. doi: 10.1038/s41405-023-00144-w.PMID: 37173321 (Impact Factor unknown)
99. Vinckenbosch F, Lammers GJ, Overeem S, Chen D, Wang G, Carter LP, Zhou K, Ramaekers JG, Vermeeren A. Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial. *Hum Psychopharmacol.* 2023 Jan;38(1):e2858. doi: 10.1002/hup.2858. (Impact Factor 1.7)
100. Wang L, Pronk AC, van Poelgeest EP, Briggs R, Claassen JAHR, Jansen S, Klop M, de Lange FJ, Meskers CCGM, Odekerken VJJ, Payne SJ, Trappenburg MC, **Thijs RD**, Uleman JF, Hoekstra AG, van der Velde N. Applying systems thinking to unravel the mechanisms underlying orthostatic hypotension related fall risk. *Geroscience.* 2023 Aug; 45(4): 2743–2755. (Impact Factor 5.6)
101. Weatherspoon S, Davis A, **Keezer M**, Zutshi D, Pack A. Dobbs Versus Jackson: Epilepsy, Reproductive Health, and Abortion. *Epilepsy Curr.* 2023 May 28;23(4):211–216. doi: 10.1177/15357597231176330. (Impact Factor 3.6)
102. Wenz ES, Schinkelshoek MS, Kallweit U, **Fronczek R**, Rezaei R, Khatami R, **Lammers GJ**, Bassetti CLA. Narcolepsy type 1 and Sydenham chorea – Report of 3 cases and review of the literature. *Sleep Med.* 2023 Dec;112:234–238. doi: 10.1016/j.sleep.2023.10.028. PMID: 37925849 (Impact Factor 4.8)
103. **van Westrhenen A**, Lazeron RHC, van Dijk JP, Leijten FSS, **Thijs RD**; Dutch TeleEpilepsy Consortium. Multimodal nocturnal seizure detection in children with **epilepsy**: A prospective, multicenter, long-term, in-home trial. *Epilepsia.* 2023 Aug;64(8):2137–2152. doi: 10.1111/epi.17654. PMID: 37195144 (Impact Factor 5.6)
104. Winsvold BS, Harder AVE, Ran C, Chalmer MA, Dalmasso MC, Ferkingstad E, Tripathi KP, Bacchelli E, Børte S, Fourier C, Petersen AS, Vijfhuizen LS, Magnusson SH, O'Connor E, Bjornsdottir G, Häppölä P, Wang YF, Callesen I, Kelderman T, Gallardo VJ, de Boer I, Olofsgård FJ, Heinze K, Lund N, Thomas LF, Hsu CL, Pirinen M, Hautakangas H, Ribasés M, Guerzoni S, Sivakumar P, Yip J, Heinze A, Küçükali F, Ostrowski SR, Pedersen OB, Kristoffersen ES, Martinsen AE, Artigas MS, Lagrata S, Cainazzo MM, Adebimpe J, Quinn O, Göbel C, Cirkel A, Volk AE, Heilmann-Heimbach S, Skogholt AH, Gabrielsen ME, Wilbrink LA, Danno D, Mehta D, Guðbjartsson DF; HUNT All-In Headache, The International Headache Genetics Consortium, DBDS Genomic Consortium; Rosendaal FR, Willems van Dijk K, **Fronczek R**, Wagner M, Scherer M, Göbel H, Slegers K, Sveinsson OA, Pani L, Zoli M, Ramos-Quiroga JA, Dardiotis E, Steinberg A, Riedel-Heller S, Sjöstrand C, Thorgeirsson TE, Stefansson H, Southgate L, Trembath RC, Vandrovcova J, Noordam R, Paemeleire K, Stefansson K, Fann CS, Waldenlind E, Tronvik E, Jensen RH, Chen SP, Houlden H, Terwindt GM, Kubisch C, Maestrini E, Vikelis M, Pozo-Rosich P,

- Belin AC, Matharu M, van den Maagdenberg AMJM, Hansen TF, Ramirez A, Zwart JA; International Consortium for Cluster Headache Genetics. Cluster Headache Genomewide Association Study and Meta-Analysis Identifies Eight Loci and Implicates Smoking as Causal Risk Factor. *Ann Neurol*. 2023 Oct;94(4):713–726. doi: 10.1002/ana.26743. Epub 2023 Aug 7. PMID: 37486023 (Impact factor 11.2)
105. Xiao F, Caciagli L, Wandschneider B, Fleury M, Binding L, Giampiccolo D, Hill A, Galovic M, Foong J, Zhou D, **Sander JW**, Duncan JS, Koepp MJ. Verbal fluency functional magnetic resonance imaging detects anti-seizure effects and affective side effects of perampanel in people with focal epilepsy. *Epilepsia*. 2023 Feb;64(2):e9–e15. doi: 10.1111/epi.17493. (Impact Factor 5.6)
106. Xiao F, Caciagli L, Wandschneider B, Sone D, Young AL, Vos SB, Winston GP, Zhang Y, Liu W, An D, Kanber B, Zhou D, **Sander JW**, Thom M, Duncan JS, Alexander DC, Galovic M, Koepp MJ. Identification of different MRI atrophy progression trajectories in epilepsy by subtype and stage inference. *Brain*. 2023 Nov 2;146(11):4702–4716. doi: 10.1093/brain/awad284. PMID: 37807084 (Impact Factor 14.5)
107. Zhou Y, Hao N, **Sander JW**, Lin X, Xiong W, Zhou D. KCNH2 variants in a family with epilepsy and Long QT syndrome: a case report and literature review. *Epileptic Disord*. 2023 Aug;25(4):492–499. doi: 10.1002/epd2.20046. PMID: 36946251 (Impact Factor 2.3)